Pulmonary Arterial Hypertension Market Size, Share, Growth Analysis, By Drug Class (Endothelin Receptor Antagonists, PDE-5 Inhibitors), By Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2025-2032
폐동맥 고혈압 세계 시장 규모는 2023년 77억 9,000만 달러로 예측 기간(2025-2032년) 동안 CAGR 5.3%, 2024년 82억 달러에서 2032년 124억 달러로 성장할 것으로 예상됩니다.
폐동맥 고혈압(PAH) 시장은 유병률 증가, 희귀질환 치료제 개발에 대한 정부 지원 강화, 노인 인구 증가 등 몇 가지 주요 요인에 의해 성장할 것으로 예상됩니다. 체계적인 검토에 따르면, PAH의 유병률은 인구 10만 명당 0.4%에서 1.4%이며, 고혈압을 앓고 있는 30-79세 인구는 전 세계적으로 약 12억 8,000만 명으로 추산되며, 주로 중저소득 국가에서 주로 발생하며, WHO는 2010년부터 2030년까지 고혈압 유병률을 33% 감소시킬 것을 목표로 하고 있습니다. 고혈압 유병률을 33% 감소시키겠다는 중요한 목표를 설정하고 이 분야에 대한 더 많은 연구와 치료법의 필요성을 강조하고 있습니다. 이러한 연구 결과를 종합하면, PAH 치료의 진전이 기대됩니다.
목차
소개
조사 방법
- 정보 조달
- 2차 데이터와 1차 데이터 방법
- 시장 규모 예측
- 시장 가정과 제한
주요 요약
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porters 분석
주요 시장 인사이트
- 핵심성공요인
- 경쟁 정도
- 주요 투자 기회
- 시장 생태계
- 시장 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
폐동맥 고혈압 시장 규모 : 약물 종류별
- 시장 개요
- 엔도텔린 수용체 길항제(ERA)
- PDE-5억제제
- 프로스타사이클린 및 프로스타사이클린 유사체
- SGC 자극제
폐동맥 고혈압 시장 규모 : 유형별
폐동맥 고혈압 시장 규모 : 투여 경로별
폐동맥 고혈압 시장 규모 : 유통 채널별
폐동맥 고혈압 시장 규모
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5개사의 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채용한 전략
- 시장의 최근 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업 개요
- 기업 개요
- 제품 포트폴리오 분석
- 부문별 점유율 분석
- 매출 전년비 비교(2022-2024년)
주요 기업 개요
- United Therapeutics Corporation(United States)
- Bayer AG(Germany)
- GlaxoSmithKline plc(United Kingdom)
- Gilead Sciences, Inc.(United States)
- Novartis International AG(Switzerland)
- Pfizer Inc.(United States)
- Merck & Co., Inc.(United States)
- Bristol-Myers Squibb Company(United States)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Viatris Inc.(United States)
- Sun Pharmaceutical Industries Ltd.(India)
- Alembic Pharmaceuticals Ltd.(India)
- Aerami Therapeutics Holdings Inc.(United States)
- Asklepion Pharmaceuticals LLC(United States)
- Keros Therapeutics(United States)
- Liquidia Corporation(United States)
- Ferrer(Spain)
- Gossamer Bio(United States)
결론과 추천사항
KSM
Global Pulmonary Arterial Hypertension Market size was valued at USD 7.79 billion in 2023 and is poised to grow from USD 8.2 billion in 2024 to USD 12.4 billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).
The pulmonary arterial hypertension (PAH) market is poised for growth due to several key factors, including the increasing incidence of the disease, enhanced government support for orphan drug development, and a growing elderly population. A systematic review highlighted the prevalence of PAH, indicating it affects between 0.4% and 1.4% of individuals per 100,000, with an estimated 1.28 billion people aged 30-79 globally affected by hypertension, predominantly in low- and middle-income countries. The WHO has set significant targets to reduce hypertension prevalence by 33% from 2010 to 2030, emphasizing the need for further research and treatment options in this area. Collectively, these insights set a promising stage for advancements in the PAH treatment landscape.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pulmonary Arterial Hypertension market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Pulmonary Arterial Hypertension Market Segmental Analysis
Global Pulmonary Arterial Hypertension Market is segmented by Drug Class, Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs and SGC Stimulators. Based on Type, the market is segmented into Branded and Generics. Based on Route of Administration, the market is segmented into Oral, Intravenous/ subcutaneous and Inhalational. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Pulmonary Arterial Hypertension Market
The global pulmonary arterial hypertension (PAH) market is experiencing significant growth due to the increasing prevalence of this rare yet progressive condition, which is characterized by elevated blood pressure in the arteries leading to the lungs. Factors contributing to this rise include aging populations, a growing incidence of risk factors such as obesity, and advancements in diagnostic techniques. Consequently, there is a heightened demand for effective PAH treatments. Furthermore, the development of innovative therapies, including prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, has bolstered market growth due to their improved efficacy and safety profiles, ultimately driving greater patient interest and need for these medications.
Restraints in the Global Pulmonary Arterial Hypertension Market
The global market for pulmonary arterial hypertension (PAH) faces certain constraints due to the limited pool of patients affected by this rare disease. Unlike more prevalent chronic conditions, PAH has a low incidence rate, which can significantly impact the commercial potential of therapeutic drugs designed for treatment and may deter investment in research and development. Additionally, diagnosing PAH requires a series of complex tests, including echocardiography, right heart catheterization, and pulmonary function assessments. Furthermore, symptoms such as fatigue and shortness of breath are often vague and can be misattributed to other health issues, resulting in delayed or incorrect diagnoses that hinder patient access to appropriate care.
Market Trends of the Global Pulmonary Arterial Hypertension Market
The Global Pulmonary Arterial Hypertension (PAH) market is witnessing a significant shift towards personalized medicine, driven by technological advancements and a deeper comprehension of the disease's genetic underpinnings. Pharmaceutical companies are heavily investing in research and development initiatives aimed at discovering biomarkers that can enhance the predictability of disease progression and treatment efficacy. This trend is fostering the creation of tailored therapies that specifically address varying genetic mutations associated with PAH, thereby improving patient outcomes. As a result, the market is poised for robust growth, characterized by innovation, a focus on individualized treatment regimens, and a commitment to precision healthcare solutions.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
Global Pulmonary Arterial Hypertension Market Size by Drug Class & CAGR (2025-2032)
- Market Overview
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
Global Pulmonary Arterial Hypertension Market Size by Type & CAGR (2025-2032)
- Market Overview
- Branded
- Generics
Global Pulmonary Arterial Hypertension Market Size by Route of Administration & CAGR (2025-2032)
- Market Overview
- Oral
- Intravenous/ subcutaneous
- Inhalational
Global Pulmonary Arterial Hypertension Market Size by Distribution Channel & CAGR (2025-2032)
- Market Overview
- Hospitals
- Retail Pharmacies
- Online Pharmacies
Global Pulmonary Arterial Hypertension Market Size & CAGR (2025-2032)
- North America (Drug Class, Type, Route of Administration, Distribution Channel)
- Europe (Drug Class, Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Type, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- United Therapeutics Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alembic Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aerami Therapeutics Holdings Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Asklepion Pharmaceuticals LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Keros Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Liquidia Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ferrer (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gossamer Bio (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
